Emergent BioSolutions Secures $21.5 Million Delivery Order for BioThrax® from the U.S. Department of War
GAITHERSBURG, Md., Jan. 08, 2026 (GLOBE NEWSWIRE) — Emergent BioSolutions (NYSE: EBS) has announced a strategic delivery order valued at up to $21.5 million from the U.S. Department of War. This order, aimed at supplying BioThrax® (Anthrax Vaccine Adsorbed), is set for execution in 2026 and reinforces the ongoing commitment of Emergent to safeguard the health of service members.
Details of the Delivery Order
The recent order falls under Emergent’s existing indefinite-delivery/indefinite-quantity (IDIQ) contract (W911SR24D0001). This contract is overseen by the Capability Program Executive for Chemical, Biological, Radiological and Nuclear Defense (CPE CBRND) in collaboration with the Defense Health Agency. Deliveries associated with this order are slated to occur in 2026 and will include a one-year base period with two optional extension periods for 2027 and 2028.
Significance of BioThrax®
BioThrax® plays a critical role in public health, particularly for individuals aged 18 to 65 years at high risk of anthrax exposure. It is indicated for both:
- Pre-exposure prophylaxis against disease caused by Bacillus anthracis.
- Post-exposure prophylaxis, when administered alongside recommended antibacterial drugs.
The vaccine's effectiveness for post-exposure scenarios has been substantiated through studies conducted in animal models of inhalational anthrax.
Commitment to Safety and Health
Emergent BioSolutions emphasizes its commitment to health and safety through the following important information regarding BioThrax®:
- Contraindications: Severe allergic reactions, such as anaphylaxis, after a previous dose.
- Warnings: Use with caution in individuals sensitive to latex. Pregnant individuals should consult healthcare providers.
- Common Adverse Reactions: Local reactions like tenderness and pain as well as systemic reactions such as fatigue and headaches were observed in clinical studies.
For comprehensive safety information, it is recommended to consult the full prescribing information of BioThrax®.
Statement from Emergent BioSolutions
Paul Williams, Senior Vice President and Head of Products Business at Emergent, stated, “As part of our mission to protect and save lives, we’re proud to help protect those who protect us, including our nation’s service members. We’re pleased to continue our partnership with the U.S. Department of War to supply BioThrax® to prepare military personnel at high risk of anthrax exposure.”
About Emergent BioSolutions
Emergent BioSolutions has dedicated over 25 years to preparing entities entrusted with public health protection. They provide life-saving solutions for various health threats such as smallpox, mpox, botulism, Ebola, and anthrax-related emergencies. For additional information about their work in global health, visit their website and connect through various social media platforms.